The EFPIA has revealed the appointment of Nathalie Moll as its new director general.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has revealed the appointment of Nathalie Moll as its new director general. Currently secretary general of the European Association for Bioindustries (EuropaBio), she will join EFPIA in April 2017.
Commenting on the appointment, Joe Jimenez, President of EFPIA, said “Nathalie has an excellent track record of leadership and engagement across the life science sector. We are confident she is the right person to lead EFPIA, working with stakeholders to address the challenges faced by healthcare systems in Europe.”
Moll became secretary general of EuropaBio. Moll, currently EuropaBio’s director for agricultural biotechnology in April 2010, replacing Willy De Greef.
“I am delighted to be joining EFPIA at a time when pharmaceutical innovation is having such a dramatic effect on the lives of patients across Europe,” she said. “I look forward to working with EFPIA Members, staff and the wider research, healthcare and policy community to foster an environment that supports continued innovation and drives better outcomes for patients.”
Eric Cornut will continue to lead EFPIA as interim director general until Moll joins the organisation in April.
Philip Ward is the European Editor for Applied Clinical Trials
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Telemedicine Considerations When Conducting Decentralized Clinical Trials
January 14th 2025Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.